Unveiling 8 Analyst Insights On Corcept Therapeutics
Portfolio Pulse from Benzinga Insights
Corcept Therapeutics (NASDAQ:CORT) has been analyzed by 8 analysts, showing a range of bullish to somewhat bullish sentiments. The average 12-month price target has increased to $46.5, reflecting a 9.72% rise from the previous target. The company has shown strong financial performance with significant revenue growth, high net margins, and efficient asset management.
July 30, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics has received predominantly bullish ratings from analysts, with an average 12-month price target of $46.5, up 9.72% from the previous target. The company has demonstrated strong financial performance, including a 38.95% revenue growth rate, high net margins, and efficient asset management.
The predominantly bullish ratings and increased price targets from analysts indicate positive market sentiment towards Corcept Therapeutics. The company's strong financial performance, including significant revenue growth and high net margins, further supports a positive short-term outlook for the stock.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100